Analyst Silvan Tuerkcan from JMP Securities has recently started covering Elevation Oncology (NASDAQ:ELEV) with a Market Outperform rating and a
JMP Securities Analyst Initiates Coverage on Elevation Oncology with Market Outperform Rating and 7 Price Target
Mar 2, 2024
